For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Infliximab - Psoriasis
PAD Profile : Infliximab - Psoriasis
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Adalimumab
- Etanercept
- Ustekinumab (Psoriasis)
- Secukinumab
- Apremilast
- Ixekizumab
- Brodalumab (Psoriasis)
- Guselkumab (Psoriasis)
- Tildrakizumab
- Certolizumab pegol
- Risankizumab
Other Indications
- Ankylosing spondylitis
- Inflammatory bowel disease
- Psoriatic arthritis
- Rheumatoid arthritis
- Immunotherapy related colitis
- Inflammatory bowel disease - paediatric use
- Uveitis
- Connective tissue disease
- Graft versus Host Disease (GVHD)
- Behcet's syndrome
- Pouchitis
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.
The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends the use of infliximab subcutaneous injection or infliximab intravenous infusion. Clinicians & patients will be able to choose the most appropriate product for them at the point of prescribing.
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriasis High Cost immunomodulator Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. The agreed process and associated documentation is saved here https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6549
The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist.
Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.